Author: Ravi Shankar

CERTIFICATE MATURITY	261028
FIXED RATE (STEERING RATE + 10 b.p.)	1.85 %
VOLUME BOUGHT	10.00 BLN
TRADE DAY	261023
SETTLEMENT DAY	261026

Auction date	2026-10-23
Loan	3114
Coupon	0.125 %
ISIN-code	SE0013748258
Maturity	2030-06-01
Tendered volume, SEK mln	200 +/- 200
Total bid volume, SEK mln	1,100
Volume sold, SEK mln	200
Number of bids	11
Number of accepted bids	1
Average yield	0.789 %
Lowest yield	0.789 %
Highest accepted yield	0.789 %
% accepted at highest yield	100.00

 

Auction date	2026-10-23
Loan	3111
Coupon	0.125 %
ISIN-code	SE0007045745
Maturity	2032-06-01
Tendered volume, SEK mln	200 +/- 200
Total bid volume, SEK mln	650
Volume sold, SEK mln	200
Number of bids	7
Number of accepted bids	4
Average yield	0.940 %
Lowest yield	0.930 %
Highest accepted yield	0.949 %
% accepted at highest yield	25.00

 

Auction date	2026-10-23
Loan	3114
Coupon	0.125 %
ISIN-code	SE0013748258
Maturity	2030-06-01
Tendered volume, SEK mln	200 +/- 200
Total bid volume, SEK mln	1,100
Volume sold, SEK mln	200
Number of bids	11
Number of accepted bids	1
Average yield	0.789 %
Lowest yield	0.789 %
Highest accepted yield	0.789 %
% accepted at highest yield	100.00

 

Auction date	2026-10-23
Loan	3111
Coupon	0.125 %
ISIN-code	SE0007045745
Maturity	2032-06-01
Tendered volume, SEK mln	200 +/- 200
Total bid volume, SEK mln	650
Volume sold, SEK mln	200
Number of bids	7
Number of accepted bids	4
Average yield	0.940 %
Lowest yield	0.930 %
Highest accepted yield	0.949 %
% accepted at highest yield	25.00

 

STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) — Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its Decipher® Prostate Genomic Classifier can predict benefit from adding abiraterone to androgen deprivation therapy (ADT) in men with clinically very high-risk nonmetastatic prostate cancer. The findings will be presented tomorrow in a proffered paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 by Dr. Sarah Howlett of University College London (UCL).

The retrospective analysis of the randomized Phase III STAMPEDE trial provides new Level 1B predictive evidence for Decipher in men with clinically very high-risk nonmetastatic prostate cancer. This predictive evidence bolsters Decipher’s high-risk claims to help physicians identify which patients are most likely to benefit from adding abiraterone to ADT. These findings build on Decipher’s long-established standing in guidelines for assessing the risk of cancer progression, as well as prior STAMPEDE analysis that was recently incorporated into the NCCN 2027 prostate cancer guidelines for high- and very high-risk disease.

For patients with very high-risk disease, the decision to add abiraterone treatment carries significant consequences. Abiraterone can improve cancer outcomes when added to ADT but also adds side effects and treatment burden. Understanding a patient’s expected benefit from the additional treatment can help physicians and patients weigh the potential benefit alongside the impact on daily life.

“For men with very high-risk disease, preventing the cancer from spreading is critical, and understanding who benefits most from additional treatment can make a meaningful difference,” said Dr. Sarah Howlett, clinical research fellow in the Research Department of Oncology at UCL and the study’s presenter. “This analysis shows that the Decipher test can identify which patients in this study population were at greatest risk of prostate cancer-specific mortality and, therefore, may gain the greatest benefit from adding abiraterone to ADT. That gives physicians and patients evidence to make more confident treatment decisions based on the biology of the individual tumor.”

Key study findings in very high-risk patients:

• Decipher predicted benefit from adding abiraterone. The treatment-by-Decipher interaction for distant metastasis was statistically significant among node-negative patients (p=0.01), indicating that treatment benefit differed according to the Decipher score.
• Patients with higher Decipher scores saw greater benefit. At five years, the absolute benefit for adding abiraterone in terms of reducing distant metastasis events was 10% for patients with high scores and 11% for those with very high scores, compared to 2% benefit for those with lower scores.
• Decipher scores identified differences in the risk of cancer spread. Higher scores were associated with greater distant-metastasis risk and worse metastasis-free and overall survival in the STAMPEDE cohort. A separate analysis including data from over 27,000 real-world patients reinforced Decipher’s prognostic value across NCCN high- and very high-risk clinical groups.

The STAMPEDE analysis included 401 patients who received ADT alone or ADT plus abiraterone. The separate real-world analysis evaluated associations between Decipher scores and patient outcomes; it was not designed to assess prediction of abiraterone benefit.

“These findings expand Decipher’s predictive evidence to another consequential treatment decision: whether adding abiraterone will provide meaningful benefit for a man with very high-risk prostate cancer,” said Elai Davicioni, Ph.D., Veracyte’s medical director, Urology. “Building on the predictive data recently presented in intermediate-risk disease at ASTRO, these results strengthen Decipher’s role in helping physicians connect tumor biology to treatment selection across the prostate cancer risk continuum. We believe this growing evidence gives physicians a stronger reason to use Decipher before making decisions that can affect both cancer outcomes and patients’ quality of life.”

Decipher is already used in the care of patients with high-risk prostate cancer. The new findings strengthen the clinical rationale for testing before treatment-intensification decisions and support the potential for broader adoption and use in this population. Another trial prospectively evaluating the use of the Decipher test to guide treatment intensification or de-intensification in high-risk prostate cancer is the phase III biomarker-driven NRG-GU009 (PREDICT-RT) study, which completed enrollment earlier this year. This trial will add prospective evidence to the findings from the STAMPEDE trial, further expanding the predictive evidence around the Decipher test for treatment intensification with apalutamide, a different androgen receptor pathway inhibitor.

ESMO 2026 presentation

• Title: Transcriptome classifier risk stratification and intensification with androgen receptor pathways inhibitors (ARPI) for clinically high-risk prostate cancer
• Presenter: Dr. Sarah Howlett, University College London
• Date and time: October 24, 2026 at 10:15–11:45 a.m. CEST

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter).  

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements regarding the potential clinical utility, impact and benefits of the Decipher Prostate Genomic Classifier; the ability of the Decipher Prostate test to predict which patients with very high-risk, nonmetastatic prostate cancer may benefit from the addition of abiraterone to ADT; the potential use of Decipher to inform treatment selection, including treatment-intensification decisions, and personalize treatment decisions; the potential for Decipher to help physicians connect tumor biology to treatment selection across the prostate cancer risk continuum; the potential for broader adoption and use in patients with very high-risk, nonmetastatic prostate cancer; the significance and clinical implications of the study findings; and the potential outcomes, validation and impact of the ongoing Phase III PREDICT-RT clinical trial. Forward-looking statements can be identified by words such as “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Investors: 
Kelly Gura  
investors@veracyte.com

Media: 
Molly Cornbleet 
media@veracyte.com 
+1 650-351-8780

STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) — Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its Decipher® Prostate Genomic Classifier can predict benefit from adding abiraterone to androgen deprivation therapy (ADT) in men with clinically very high-risk nonmetastatic prostate cancer. The findings will be presented tomorrow in a proffered paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 by Dr. Sarah Howlett of University College London (UCL).

The retrospective analysis of the randomized Phase III STAMPEDE trial provides new Level 1B predictive evidence for Decipher in men with clinically very high-risk nonmetastatic prostate cancer. This predictive evidence bolsters Decipher’s high-risk claims to help physicians identify which patients are most likely to benefit from adding abiraterone to ADT. These findings build on Decipher’s long-established standing in guidelines for assessing the risk of cancer progression, as well as prior STAMPEDE analysis that was recently incorporated into the NCCN 2027 prostate cancer guidelines for high- and very high-risk disease.

For patients with very high-risk disease, the decision to add abiraterone treatment carries significant consequences. Abiraterone can improve cancer outcomes when added to ADT but also adds side effects and treatment burden. Understanding a patient’s expected benefit from the additional treatment can help physicians and patients weigh the potential benefit alongside the impact on daily life.

“For men with very high-risk disease, preventing the cancer from spreading is critical, and understanding who benefits most from additional treatment can make a meaningful difference,” said Dr. Sarah Howlett, clinical research fellow in the Research Department of Oncology at UCL and the study’s presenter. “This analysis shows that the Decipher test can identify which patients in this study population were at greatest risk of prostate cancer-specific mortality and, therefore, may gain the greatest benefit from adding abiraterone to ADT. That gives physicians and patients evidence to make more confident treatment decisions based on the biology of the individual tumor.”

Key study findings in very high-risk patients:

• Decipher predicted benefit from adding abiraterone. The treatment-by-Decipher interaction for distant metastasis was statistically significant among node-negative patients (p=0.01), indicating that treatment benefit differed according to the Decipher score.
• Patients with higher Decipher scores saw greater benefit. At five years, the absolute benefit for adding abiraterone in terms of reducing distant metastasis events was 10% for patients with high scores and 11% for those with very high scores, compared to 2% benefit for those with lower scores.
• Decipher scores identified differences in the risk of cancer spread. Higher scores were associated with greater distant-metastasis risk and worse metastasis-free and overall survival in the STAMPEDE cohort. A separate analysis including data from over 27,000 real-world patients reinforced Decipher’s prognostic value across NCCN high- and very high-risk clinical groups.

The STAMPEDE analysis included 401 patients who received ADT alone or ADT plus abiraterone. The separate real-world analysis evaluated associations between Decipher scores and patient outcomes; it was not designed to assess prediction of abiraterone benefit.

“These findings expand Decipher’s predictive evidence to another consequential treatment decision: whether adding abiraterone will provide meaningful benefit for a man with very high-risk prostate cancer,” said Elai Davicioni, Ph.D., Veracyte’s medical director, Urology. “Building on the predictive data recently presented in intermediate-risk disease at ASTRO, these results strengthen Decipher’s role in helping physicians connect tumor biology to treatment selection across the prostate cancer risk continuum. We believe this growing evidence gives physicians a stronger reason to use Decipher before making decisions that can affect both cancer outcomes and patients’ quality of life.”

Decipher is already used in the care of patients with high-risk prostate cancer. The new findings strengthen the clinical rationale for testing before treatment-intensification decisions and support the potential for broader adoption and use in this population. Another trial prospectively evaluating the use of the Decipher test to guide treatment intensification or de-intensification in high-risk prostate cancer is the phase III biomarker-driven NRG-GU009 (PREDICT-RT) study, which completed enrollment earlier this year. This trial will add prospective evidence to the findings from the STAMPEDE trial, further expanding the predictive evidence around the Decipher test for treatment intensification with apalutamide, a different androgen receptor pathway inhibitor.

ESMO 2026 presentation

• Title: Transcriptome classifier risk stratification and intensification with androgen receptor pathways inhibitors (ARPI) for clinically high-risk prostate cancer
• Presenter: Dr. Sarah Howlett, University College London
• Date and time: October 24, 2026 at 10:15–11:45 a.m. CEST

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter).  

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements regarding the potential clinical utility, impact and benefits of the Decipher Prostate Genomic Classifier; the ability of the Decipher Prostate test to predict which patients with very high-risk, nonmetastatic prostate cancer may benefit from the addition of abiraterone to ADT; the potential use of Decipher to inform treatment selection, including treatment-intensification decisions, and personalize treatment decisions; the potential for Decipher to help physicians connect tumor biology to treatment selection across the prostate cancer risk continuum; the potential for broader adoption and use in patients with very high-risk, nonmetastatic prostate cancer; the significance and clinical implications of the study findings; and the potential outcomes, validation and impact of the ongoing Phase III PREDICT-RT clinical trial. Forward-looking statements can be identified by words such as “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Investors: 
Kelly Gura  
investors@veracyte.com

Media: 
Molly Cornbleet 
media@veracyte.com 
+1 650-351-8780

FLORHAM PARK, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that BDR Pharmaceuticals International Pvt. Ltd. (BDR) has filed suit against the U.S. Food and Drug Administration (FDA) and related Federal Defendants in the United States District Court for the District of Columbia, principally challenging FDA’s alleged refusal to receive an abbreviated new drug application (ANDA) referencing Phathom’s new drug application (NDA) for VOQUEZNA®. In the suit, BDR alleges that FDA has improperly applied the GAIN Act to extend Phathom’s New Chemical Entity (NCE) exclusivity for VOQUEZNA (vonoprazan fumarate) tablets. Phathom is evaluating the BDR filings, but believes that FDA carefully and correctly evaluated this issue in its June 6, 2025 grant of Phathom’s December 11, 2024 Citizen Petition, in which FDA recognized 10 years of NCE exclusivity for VOQUEZNA tablets through May 3, 2032. Phathom intends to take appropriate action to protect its statutory exclusivities.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

Forward-Looking Statements
This press release contains forward-looking statements, including without limitation statements regarding: Phathom’s belief that FDA correctly evaluated and recognized the GAIN Act extension of the NCE exclusivity for VOQUEZNA tablets; Phathom’s intent to take appropriate actions to protect its statutory exclusivities; the expected duration of NCE exclusivity for VOQUEZNA tablets; and the potential timing and outcome of the litigation filed by BDR. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risk that: BDR may succeed in its challenge to FDA’s recognition of the GAIN Act extension of NCE exclusivity for VOQUEZNA tablets which would result in a reduction in the period of regulatory exclusivity and permit FDA to receive and potentially approve ANDAs referencing VOQUEZNA tablets earlier than currently anticipated; the litigation, including any appeals, may be lengthy, costly and distracting to management, and its timing and outcome are uncertain; developments in the litigation, or public perception of them, may hurt Phathom’s stock price, VOQUEZNA sales, or Phathom’s business, financial condition and prospects; Phathom may not be able to obtain and maintain intellectual property protection, including patent term extensions, and may not be able to maintain non-patent regulatory exclusivity for VOQUEZNA for the time periods it expects or at all; Phathom may be unsuccessful in defending its Orange Book-listed patents against challenges by third parties; Phathom may face competition earlier than expected if it loses any of regulatory or patent protection or non-patent regulatory exclusivity for VOQUEZNA tablets, including as a result of an adverse outcome in the BDR litigation; and other risks described in Phathom’s prior press releases and filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to revise or update such statements to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2026 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

FLORHAM PARK, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that BDR Pharmaceuticals International Pvt. Ltd. (BDR) has filed suit against the U.S. Food and Drug Administration (FDA) and related Federal Defendants in the United States District Court for the District of Columbia, principally challenging FDA’s alleged refusal to receive an abbreviated new drug application (ANDA) referencing Phathom’s new drug application (NDA) for VOQUEZNA®. In the suit, BDR alleges that FDA has improperly applied the GAIN Act to extend Phathom’s New Chemical Entity (NCE) exclusivity for VOQUEZNA (vonoprazan fumarate) tablets. Phathom is evaluating the BDR filings, but believes that FDA carefully and correctly evaluated this issue in its June 6, 2025 grant of Phathom’s December 11, 2024 Citizen Petition, in which FDA recognized 10 years of NCE exclusivity for VOQUEZNA tablets through May 3, 2032. Phathom intends to take appropriate action to protect its statutory exclusivities.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

Forward-Looking Statements
This press release contains forward-looking statements, including without limitation statements regarding: Phathom’s belief that FDA correctly evaluated and recognized the GAIN Act extension of the NCE exclusivity for VOQUEZNA tablets; Phathom’s intent to take appropriate actions to protect its statutory exclusivities; the expected duration of NCE exclusivity for VOQUEZNA tablets; and the potential timing and outcome of the litigation filed by BDR. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risk that: BDR may succeed in its challenge to FDA’s recognition of the GAIN Act extension of NCE exclusivity for VOQUEZNA tablets which would result in a reduction in the period of regulatory exclusivity and permit FDA to receive and potentially approve ANDAs referencing VOQUEZNA tablets earlier than currently anticipated; the litigation, including any appeals, may be lengthy, costly and distracting to management, and its timing and outcome are uncertain; developments in the litigation, or public perception of them, may hurt Phathom’s stock price, VOQUEZNA sales, or Phathom’s business, financial condition and prospects; Phathom may not be able to obtain and maintain intellectual property protection, including patent term extensions, and may not be able to maintain non-patent regulatory exclusivity for VOQUEZNA for the time periods it expects or at all; Phathom may be unsuccessful in defending its Orange Book-listed patents against challenges by third parties; Phathom may face competition earlier than expected if it loses any of regulatory or patent protection or non-patent regulatory exclusivity for VOQUEZNA tablets, including as a result of an adverse outcome in the BDR litigation; and other risks described in Phathom’s prior press releases and filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to revise or update such statements to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2026 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with multiple intracranial complete responses

88% 6-month landmark PFS compares favorably to current standards of care and to investigational therapies; follow-up ongoing with majority of patients continuing on treatment

Competitive safety profile with no significant off-target toxicity and no treatment-related discontinuations

Redwood-1 global Phase 3 registrational trial initiation in 1L EGFR atypical NSCLC expected in 1H 2027

Company to host a conference call and webcast today at 8:00 am ET featuring Dr. Joshua Sabari

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today presented potential best-in-class data for enozertinib in first-line NSCLC patients with EGFR atypical mutations at ESMO Congress 2026 and announced plans to advance enozertinib into a global Phase 3 trial.

“These enozertinib systemic and intracranial response data set a new benchmark in 1L EGFR atypical NSCLC,” said Pratik S. Multani, M.D., chief medical officer. “The data are particularly impressive given that nearly two-thirds of our patients had baseline brain metastases, which is more than double the rate seen in competitor datasets, and which has historically been associated with poorer outcomes.”

“Supported by these potential best-in-class data and having successfully completed End-of-Phase 1 interactions with FDA, we are rapidly advancing enozertinib into a global Phase 3 registrational trial,” said Jacob M. Chacko, M.D., president and chief executive officer. “With rinzimetostat’s first Phase 3 trial in prostate cancer initiated earlier this year and enozertinib’s first Phase 3 trial in lung cancer planned for 1H 2027, ORIC has become a diversified, late-stage oncology company with two programs offering opportunities for broader development across indications with significant unmet need and meaningful commercial potential.”

Enozertinib Phase 1b Data in 1L EGFR Atypical NSCLC
Enozertinib is being evaluated in an ongoing Phase 1b trial in patients with locally advanced or metastatic NSCLC with EGFR atypical and EGFR exon 20 insertion mutations. Notably, enrollment allows patients with previously untreated brain metastases (i.e., active, untreated brain metastases). Key objectives of the trial included safety and determination of the recommended Phase 2 dose, along with assessment of antitumor activity based on investigator-assessed objective response rate (ORR), blinded independent central review (BICR)-assessed ORR, CNS-ORR according to modified RECIST 1.1 and/or Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM), as well as DOR and PFS.

As of the September 4, 2026 cutoff date, data are presented for 26 patients who were treated with 80 mg once daily oral enozertinib, including 23 patients with P-loop and alpha C-helix compressing (PACC) mutations and 3 patients with L861Q mutations without a co-occurring PACC mutation. Brain metastases were present in 65% of patients at baseline, which is more than double the rate versus competitor datasets. Notably, 46% of all patients had previously untreated brain metastases.

Safety Analysis
Enozertinib was well tolerated with predominantly Grade 1 or 2 treatment-related adverse events (TRAEs) and no significant off-target toxicities. Most frequent TRAEs included diarrhea, paronychia, and dermatitis acneiform. Six patients (23%) experienced Grade 3 TRAEs, all of which were resolved with dose modifications. There were no Grade 4 or 5 TRAEs and no treatment discontinuations related to TRAEs.

Meaningful Systemic Antitumor Activity
Tumor reductions were observed across all response-evaluable patients¹. Reductions were also observed across a wide range of mutations, including the most prevalent PACC mutations (e.g., G719X, S768I), a broad spectrum of PACC complex mutations, and L861Q mutations. Enozertinib demonstrated meaningful systemic activity, including:

• 84% (21 of 25) confirmed systemic ORR by investigator.
• 80% (20 of 25) confirmed systemic ORR by BICR.

Deep EGFR-mutant ctDNA molecular responses were achieved by Cycle 3 Day 1 in all response-evaluable patients across diverse mutations²:

• 100% of patients achieved MR90, defined as a ≥90% EGFR-mutant ctDNA reduction.
• 82% of patients achieved full clearance, which has been associated with improved long-term survival outcomes in prior Phase 3 NSCLC trials.

Compelling Intracranial Antitumor Activity
Enozertinib continues to demonstrate potential best-in-class intracranial efficacy. Notably, no new CNS lesions were observed in patients with or without baseline CNS metastases.

All response-evaluable patients with measurable CNS disease (90% without prior treatment for their CNS metastases) achieved CNS tumor reductions per investigator-assessment³. Enozertinib demonstrated compelling intracranial activity, including:

• 70% confirmed intracranial ORR by investigator.

Intracranial efficacy was also evaluated utilizing the more stringent BICR RANO-BM assessment criteria. Based on this assessment, CNS tumor reductions were observed in nearly all response-evaluable patients, including in patients with previously untreated CNS metastases⁴. Enozertinib demonstrated compelling intracranial activity, including:

• 67% (10 of 15) intracranial ORR by BICR RANO-BM.
• 40% (6 of 15) intracranial complete response rate by BICR RANO-BM, including in three patients with non-measurable CNS disease.

Promising Early Durability
Median progression-free survival and median duration of response data are immature. The Kaplan-Meier 6-month landmark PFS is 88%. Follow-up is ongoing with the majority of patients continuing on treatment.

Redwood-1 Phase 3 Initiation
Supported by potential best-in-class data presented at ESMO Congress 2026 and based on End-of-Phase 1 interactions with the FDA, ORIC plans to initiate Redwood-1, a global Phase 3 registrational trial in EGFR atypical NSCLC in 1H 2027. This trial plans to enroll approximately 360 patients with PACC and L861X mutations, including those with untreated brain metastases, randomized to receive 80 mg once daily oral enozertinib or physician’s choice of osimertinib or afatinib. Dual primary endpoints include ORR by BICR for potential accelerated approval as well as PFS by BICR for full approval. Key secondary endpoints include overall survival and intracranial ORR by BICR RANO-BM.

Poster Details
Enozertinib (ORIC-114), a Brain Penetrant, Highly Selective EGFR Inhibitor, in Treatment-Naive Metastatic NSCLC with EGFR Atypical Mutations
Presentation Number: 2627P
Session Date & Time: Monday, October 26, 2026; 12:00 – 12:45 p.m. CET
Session Title: Metastatic NSCLC
The poster presentation can be found on the ESMO Congress website here, and in the publication section of ORIC’s website here.

Conference Call and Webcast Details
The conference call and webcast will take place on Friday, October 23, 2026, at 8:00 a.m. ET. ORIC leadership plans to have Dr. Joshua Sabari, Assistant Professor of Medicine at NYU Grossman School of Medicine, join the call to share his perspective on the enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. The live webcast and an audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.

__________________
¹ n=25 patients with opportunity for two post-baseline tumor assessments.
² n=22 patients with EGFR mutation in baseline plasma and opportunity for two post-baseline systemic tumor assessments. September 15, 2026 cutoff.
³ n=10 patients with measurable target CNS lesions per investigator assessment.
⁴ n=15 patients with baseline CNS metastases per BICR assessment.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR atypical and EGFR exon 20 mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the continued clinical development of enozertinib; the potential advantages of enozertinib; statements regarding the potential best-in-class profile of enozertinib; clinical outcomes from studies of enozertinib, which may materially change as patient enrollment continues or more patient data become available; the development plans and timelines for rinzimetostat and enozertinib, including the expected initiation of the Redwood-1 trial; plans underlying ORIC’s clinical trials and development; and statements by the company’s chief medical officer and chief executive officer. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as a clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of rinzimetostat, enozertinib or any other product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements or its clinical trial collaboration and supply agreements; the potential market for ORIC’s product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the SEC) on August 3, 2026, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED inhibitor rinzimetostat maintained effectiveness

Preclinical results, supported by translational data in mCRPC patient samples, show rinzimetostat reinforces a luminal, AR-dependent state, restricts lineage plasticity and enhances sensitivity to AR inhibition

Findings reinforce rinzimetostat’s differentiated profile and support development across the prostate cancer disease spectrum, including in the ongoing Himalayas-1 Phase 3 trial

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced preclinical and translational data from an ePoster presentation at ESMO Congress 2026 highlighting the potential of rinzimetostat to enhance sensitivity to androgen receptor inhibition in prostate cancer.

“These results strengthen the rationale for combining PRC2 inhibition with androgen receptor targeted therapies across castration-sensitive and castration-resistant prostate cancer by limiting tumor adaptability and enhancing sensitivity to AR inhibition,” said Lori Friedman, PhD, chief scientific officer. “Verification of our preclinical results in patient samples, together with the potential advantages of targeting PRC2 via EED, reinforce our confidence in rinzimetostat’s potential best-in-class profile and support its evaluation across the prostate cancer disease spectrum, including in our ongoing Himalayas-1 Phase 3 trial.”

Rinzimetostat, a Next Generation PRC2 Inhibitor, Enhances Luminal Fate and AR Signaling While Restricting Lineage Plasticity in Preclinical Models and Demonstrates Mechanistic Proof-of-Concept in Samples from Patients with mCRPC

ePoster Number: 1128eP
Session Title: Developmental Therapeutics
Key findings of the presentation:

• Preclinical results suggest potential advantages of targeting PRC2 via EED with rinzimetostat over targeting EZH2:
  • Prostate cancer cells that rapidly developed resistance to mevrometostat acquired a mutation in EZH2 against which rinzimetostat potency was maintained; no emergence of rinzimetostat-resistant cells was observed.
  • No hematologic tumorigenesis was observed in the rinzimetostat rat toxicology study, in contrast to rat tumorigenesis demonstrated with EZH2 inhibitor tazemetostat; these results are consistent with mouse genetic studies of PRC2 components and suggest the tumorigenesis risk may be elevated with selective EZH2 targeting.
  • Comparative preclinical studies demonstrated drug properties supporting rinzimetostat’s potential best-in-class profile, including favorable solubility, oral bioavailability, half-life and CYP profile.
• Rinzimetostat restored access to AR binding motifs and restricted accessibility at sites associated with lineage plasticity in preclinical prostate cancer models, supporting a mechanism that reinforces AR dependence and limits tumor adaptation.
  • Rinzimetostat synergized with AR inhibition in preclinical prostate cancer studies.
  • KLK2 and STEAP1 luminal markers increased following rinzimetostat treatment in preclinical studies.
• Samples from patients with mCRPC treated with single-agent rinzimetostat demonstrated biological changes consistent with the preclinical findings:
  • Plasma cfDNA methylation profiling showed epigenetic shifts indicative of increased AR signaling after one treatment cycle in most patients assessed.
  • Paired tumor biopsies showed increased levels of luminal and AR-associated markers PSMA and KLK2.

The ePoster presentation can be found on the ESMO Congress website here, and in the publication section of ORIC’s website here.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR atypical and EGFR exon 20 mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the continued clinical development of rinzimetostat; the potential advantages of rinzimetostat, including by targeting PRC2 via EED instead of EZH2; statements regarding the potential best-in-class profile of rinzimetostat; the development plans and timelines for rinzimetostat; plans underlying ORIC’s clinical trials and development; and statements by the company’s chief scientific officer. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of rinzimetostat, enozertinib or any other product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements or its clinical trial collaboration and supply agreements; the potential market for ORIC’s product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the SEC) on August 3, 2026, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Contact:

Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) — On October 21, Professor Joseph Sifakis, a Turing Award laureate and Chief Scientific Advisor of the CaoCao Mobility AI Innovation Research Center, visited the center for in-depth discussions with CaoCao’s technology team. On the same day, CaoCao launched a research project on Trustworthy Decision-Making and Multi-Agent Coordination for Robotaxi Curbside Operations. Professor Sifakis witnessed the launch and offered valuable recommendations based on his extensive research experience.

Professor Sifakis is one of the pioneers of model checking. He received the 2007 Turing Award for his contributions to the development of model-checking theory and its applications. He has long been engaged in research on complex intelligent systems and Trustworthy Autonomous Systems, areas closely related to the safety and trustworthiness challenges facing Robotaxi operations at scale.

In June this year, Professor Sifakis was formally invited to serve as Chief Scientific Advisor of the CaoCao Mobility AI Innovation Research Center to provide academic guidance for CaoCao’s AI transformation and the development of its autonomous driving technologies. At the 2026 World Artificial Intelligence Conference, he outlined three fundamental principles for trustworthy Robotaxis: Safe by Design, System Coordination, and Runtime Assurance. He also noted that CaoCao’s RoboX ecosystem closely aligns with the systems-engineering principles underlying Trustworthy Autonomous Systems.

Passenger pick-up and drop-off are critical to the Robotaxi experience. This newly launched research project focuses on safety and trustworthiness in this everyday mobility scenario, exploring how the theory of Trustworthy Autonomous Systems can be translated into verifiable engineering methods.

Drawing on 11 years of real-world operating data and experience from CaoCao’s mobility services, the project will examine the conditions under which curbside stopping locations can be used, passenger boarding and alighting paths, vehicle stopping behavior, and system coordination. By exploring methods for cross-validating results from simulation and real-vehicle testing, the project aims to build a body of reusable, scenario-based evidence to support safety validation for the trustworthy transfer of Robotaxi operations across cities and their deployment worldwide.

Contact:
Jing Liu   
Jing.Liu3@caocaoglobal.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/66d7d57d-af7c-4812-91ed-15420008c24e